Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 54 for:    colon cancer | ( Map: Mississippi, United States )
Previous Study | Return to List | Next Study

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01150045
Recruitment Status : Active, not recruiting
First Posted : June 24, 2010
Last Update Posted : January 24, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

Tracking Information
First Submitted Date  ICMJE June 23, 2010
First Posted Date  ICMJE June 24, 2010
Last Update Posted Date January 24, 2019
Study Start Date  ICMJE June 2010
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 31, 2015)
Disease-free survival [ Time Frame: Up to 6 years ]
Original Primary Outcome Measures  ICMJE
 (submitted: June 23, 2010)
Disease-free survival
Change History Complete list of historical versions of study NCT01150045 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 31, 2015)
Overall survival [ Time Frame: Up to 6 years ]
Original Secondary Outcome Measures  ICMJE
 (submitted: June 23, 2010)
  • Recurrence-free survival
  • Overall survival at 3 years
  • Toxicity of celecoxib
  • Cardiovascular-specific events
  • Differences in toxicity, particularly cumulative peripheral neuropathy, of 6 vs 12 courses of FOLFOX
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Official Title  ICMJE A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
Brief Summary

PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer.

Detailed Description

OUTLINE: This is a multicenter study. Patients are stratified according to number of positive lymph nodes* (1-3 vs 4 or more) and concurrent regular low-dose of aspirin (yes vs no). Patients are randomized to 1 of 4 treatment arms. Please see the "Arms" section for more information. In all arms, treatment with celecoxib or placebo continues for 3 years in the absence of disease progression or unacceptable toxicity. Blood and tissue samples maybe collected for biomarker analysis and pharmacogenomic studies. The primary and secondary objectives for the research study are described below.

Primary objective:

1. To compare disease-free survival of patients with stage III colon cancer randomized to standard chemotherapy only FOLFOX or standard chemotherapy FOLFOX with 3 years of celecoxib 400 mg daily.

Secondary objectives:

  1. To contribute to an international prospective pooled analysis that will compare disease-free survival of patients with stage III colon cancer randomized to 6 treatments of adjuvant FOLFOX chemotherapy or 12 treatments of adjuvant FOLFOX chemotherapy.
  2. To compare overall survival of patients with stage III colon cancer randomized to standard chemotherapy only (FOLFOX) or standard chemotherapy (FOLFOX) with 3 years of celecoxib 400 mg daily.
  3. To contribute to an international prospective pooled analysis that will compare overall survival of patients with stage III colon cancer randomized to 6 treatments of adjuvant FOLFOX chemotherapy or 12 treatments of adjuvant FOLFOX chemotherapy or 12 treatments of adjuvant FOLFOX chemotherapy.
  4. To assess toxicities of celecoxib as maintenance adjuvant therapy in patients with stage III colon cancer.
  5. To assess differences in cardiovascular-specific events with celecoxib versus placebo in a population of stage III colon cancer survivors.
  6. To evaluate differences in toxicities, particularly cumulative peripheral neuropathy, for patients treated with 6 treatments of FOLFOX compared to those treated with 12 treatments of FOLFOX.

After completion of study therapy, patients are followed up every 6 months for up to 6 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Drug: celecoxib
    Patients receive celecoxib 400 mg administered by mouth, once daily.
  • Drug: 5-fluorouracil
    Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
  • Other: placebo
    Patients receive placebo administered by mouth, once daily.
  • Drug: oxaliplatin
    Patients receive 85 mg/m^2 intravenous over two hours.
  • Drug: leucovorin
    Patients receive 400 mg/m^2 intravenous over two hours.
Study Arms  ICMJE
  • Active Comparator: Arm A - FOLFOX and placebo (12 treatments)
    Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
    Interventions:
    • Drug: 5-fluorouracil
    • Other: placebo
    • Drug: oxaliplatin
    • Drug: leucovorin
  • Experimental: Arm B - FOLFOX and celecoxib (12 treatments)
    Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
    Interventions:
    • Drug: celecoxib
    • Drug: 5-fluorouracil
    • Drug: oxaliplatin
    • Drug: leucovorin
  • Active Comparator: Arm C - FOLFOX and placebo (6 treatments)
    Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
    Interventions:
    • Drug: 5-fluorouracil
    • Other: placebo
    • Drug: oxaliplatin
    • Drug: leucovorin
  • Experimental: Arm D - FOLFOX and celecoxib (6 treatments)
    Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
    Interventions:
    • Drug: celecoxib
    • Drug: 5-fluorouracil
    • Drug: oxaliplatin
    • Drug: leucovorin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: June 23, 2010)
2500
Original Estimated Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  1. Requirements for tumor parameters

    1. Histologically documented adenocarcinoma of the colon. The gross inferior (caudad) margin of the primary tumor must lie above the peritoneal reflection (i.e., patients with rectal cancer are not eligible). Surgeon confirmation that the entire tumor was above the peritoneal reflection is only required in cases where it is important to establish if the tumor is a rectal or colon primary.
    2. Tumors must have been completely resected. In patients with tumor adherent to adjacent structures, en bloc R0 resection must be documented in the operative report or otherwise confirmed by the surgeon. Near or positive radial margin are not exclusions as long as en bloc resection was performed. Positive proximal margin or distal margin is an exclusion.
    3. Node positive disease (N1 or N2) as designated in AJCC version 7. Either at least one pathologically confirmed positive lymph node or N1C (defined as tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastases). Patients with resected stage IV disease are not eligible.
    4. No evidence of residual involved lymph node disease or metastatic disease at the time of registration.
    5. Patients with synchronous colon cancers are eligible and staging for stratification will be based on higher N stage of the more advanced primary tumor. However, patients with synchronous colon and rectal primary tumors are not eligible.
  2. NSAID use

    Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average. Low-dose aspirin not exceeding 100 mg/day is permitted. Patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no was out period is required.

  3. Patient history

    1. No previous or concurrent malignancy, except treated basal cell or squamous cell cancer of skin, treated in situ cervical cancer, treated lobular or ductal carcinoma in situ in one breast, or any other cancer for which the patient has been disease-free for at least 5 years.
    2. No neurosensory or neuromotor toxicity ≥ grade 2 at the time of registration.
    3. No known allergy to platinum compounds.
    4. No prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs.
    5. No history of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years. Patients with ulceration, bleeding or perforation in the lower bowel are not excluded.
    6. No symptomatic pulmonary fibrosis or interstitial pneumonitis ≥ grade 2.
    7. No cardiac risk factors including:

      • Uncontrolled high blood pressure (systolic blood pressure > 150).
      • Unstable angina.
      • History of documented myocardial infarction or cerebrovascular accident.
      • New York Heart Association class III or IV heart failure.
  4. Pregancy/nursing status

    Non-pregnant and not nursing. Men and women of childbearing potential must agree to employ adequate contraception for the duration of chemotherapy and for as many as 8 weeks after the completion of chemotherapy due to the unknown teratogenic effects of FOLFOX on the developing fetus.

  5. Age and performance status

    1. ECOG performance status 0, 1 or 2.
    2. Age at least 18 years.
  6. Required initial laboratory values

    1. Granulocytes ≥ 1,500/μL
    2. Platelet count ≥ 100,000/μL
    3. Creatinine ≤ 1.5 times upper limit of normal (ULN)
    4. Total Bilirubin ≤ 1.5 times ULN in the absence of Gilbert's disease
    5. Direct bilirubin ≤ 1.5 x upper limit of normal for patients with Gilbert's syndrome
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States,   Canada,   Puerto Rico
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01150045
Other Study ID Numbers  ICMJE CALGB-80702
U10CA031946 ( U.S. NIH Grant/Contract )
CALGB-80702
CDR0000675693 ( Registry Identifier: NCI Physician Data Query )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Alliance for Clinical Trials in Oncology
Study Sponsor  ICMJE Alliance for Clinical Trials in Oncology
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Study Chair: Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute
PRS Account Alliance for Clinical Trials in Oncology
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP